✦ LIBER ✦

5-fluorouracil, etoposide, and cisplatin in the management of metastatic non-small cell lung cancer

✍ Scribed by Lawrence Flaherty; Antoinette Wozniak; Bruce Redman; Michael Kraut; Silvana Martino; Lance Heilbrun; Manuel Valdivieso

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 339 KB
Volume: 68
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19910901)68:5<944::aid-cncr2820680506>3.0.co;2-g

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cisplatin, 5-fluorouracil, and etoposide

Cisplatin, 5-fluorouracil, and etoposide for advanced non-small cell lung cancer

✍ Thomas J. Lynch Jr.; Frederick Kass; Anthony D. Elias; Arthur Skarin; Emil Frei 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB 👁 1 views

Etoposide in the management of non-small

Etoposide in the management of non-small cell lung cancer

✍ John C. Ruckdeschel 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 387 KB 👁 2 views

Treatment of advanced non-small cell lun

Treatment of advanced non-small cell lung cancer with cisplatin, 5-fluorouracil, and mitomycin C

✍ Paul J. Hesketh; Timothy P. Cooley; Harvey E. Finkel; Jonathan Wright; Ann M. He 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 493 KB 👁 1 views

Cisplatin, etoposide, and mitomycin in t

Cisplatin, etoposide, and mitomycin in the treatment of non-small cell carcinoma of the lung. A pilot study

✍ Stephen Davis; Maurizio Tomato; Lucio Crino; Mari Antonetta Colozza; Kenneth Lub 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB 👁 2 views

A total of 39 patients with non-small cell carcinoma of the lung (NSCL) were treated with cisplatin, etoposide, and mitomycin. A major response rate (complete response + partial response) was seen in 15 patients (39%). Median survival for all patients was 340 days; median survival of the responding

Cisplatin, etoposide, and ifosfamide in

Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm

✍ Adriano Paccagnella; Adolfo Favaretto; Alba Brandes; Cristina Ghiotto; Driano Fo 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 434 KB 👁 2 views

Cisplatin, continuous-infusion 5-fluorou

Cisplatin, continuous-infusion 5-fluorouracil, and intermediate-dose methotrexate in the treatment of unresectable non-small cell carcinoma of the lung

✍ Catherine A. Wheeler; Lawrence N. Shulman; Steven E. Come; Lowell E. Schnipper; 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 377 KB 👁 1 views

Forty-one patients with unresectable non-small cell carcinoma of the lung (NSCCL) were treated with cisplatin 20 mg/m2/d for 5 days as a daily bolus injection, 5-fluorouracil 800 mg/m2/d by continuous infusion for 5 days, and intermediate-dose methotrexate 200 mg/m2 on days 15 and 22 of a 28-day cyc